FDA oncology advisors again pushed back on AstraZeneca’s ctDNA-driven switching strategy for camizestrant. Two separate ODAC-focused writeups (one noting a related “new paradigm” framing and one centering on the Guardant ctDNA approach) reported a 6–3 vote that the available evidence does not support switching patients based on ESR1 mutations detected in circulating tumor DNA rather than waiting for radiographic progression.